We are delighted to bring you the 2018 Annual Report for the year to 31 March 2018, and to share with you our progress and performance.
The Report can also be viewed on our website www.truscreen.com
Focus remains firmly on the Chinese market
• Signed major new sub-distributor in China to manage government sales channels.
• Commenced sales of TruScreen2 device in China in December 2017, following CFDA approval.
• Commenced 10,000 patient evaluation trial with the Chinese Obstetrics and Gynaecology Association.
• Post period end, commenced a pilot programme with the Women’s and Children’s Healthcare Division of the Centre for Disease Control in China, with more than 12,000 women expected to be involved.
• Post-period end: Confirmed installation of TruScreen devices in 190 hospitals in Xinjiang Province over the coming months; and selected as the primary screening solution for a chain of high tech female health clinics to be established in 50 municipal hospitals in China.
Building on our global presence outside of China
• Established distribution networks for several new territories.
• Commenced a research collaboration with the All India Institute of Medical Science to validate TruScreen for the screening of Indian women and to be recommended to the Government of India’s (GOI) Ministry of Health and Family Welfare for use in nationally funded screening programs.
• Commenced evaluation with Ministry of Health in Mexico for inclusion in the Mexican Government’s purchasing catalogue of preferred medical devices for public health.
• Selected for use in Mexico’s famous Health Train, bringing advanced medical technologies to remote communities.
• Commenced a pilot study in Papua New Guinea to evaluate TruScreen as a cervical cancer screening solution in
regional and remote locations.
• Selected for evaluation by the Zimbabwe Ministry of Health for use as a government solution for cervical cancer screening.
• Approved for reimbursement by major health insurer in Jordan, a global first for TruScreen.
• Recommended for inclusion in Russian clinical guidelines.